L-Arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl-:Exports & Compliance White Paper 2026

I. Executive Summary

The compound registered under CAS 1801959-12-5 and named systematically as L-arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl- is the heptapeptide GVSWGLR, widely referenced in the literature as the PE 22-28 fragment of the sortilin-derived peptide family that also includes the longer spadin sequence. Published research places this fragment in central nervous system pharmacology, principally around two-pore domain potassium channel biology including TREK-1 and around sortilin receptor interaction. That research is preclinical. The material has no approved therapeutic indication in any jurisdiction, it is supplied strictly as Research Use Only material, it is not for human or veterinary use, and it is not a finished consumer or dietary product. This paper is written for procurement, CDMO and compliance professionals.

Because the commercial demand is research demand, the value of a supply belongs to the analytical and documentation layer. A seven-residue peptide with a single tryptophan, a single serine and a C-terminal arginine is not difficult to assemble, but it is easy to deliver badly: tryptophan oxidation products, incomplete deprotection, residual trifluoroacetate and an unassigned peptide content are the four failure modes that most commonly invalidate experimental work. Buyers should therefore specify identity by accurate mass, purity by a validated stability-indicating HPLC method, assigned peptide content, counter-ion and residual-solvent data, water content and a documented related-substance profile, and should expect a supplier to decline any enquiry framed around human administration.

The sections that follow set out the physicochemical profile and the degradation chemistry specific to this sequence, the route-class manufacturing and purification options available from peptide CDMOs, the analytical method development and validation expectations that separate a research campaign from a GMP campaign, the compliance perimeter including anti-doping relevance and Know-Your-Customer practice, and the cold-chain and packaging controls that preserve material integrity. Regional coverage addresses the Chinese, Indian and European ecosystems.

II. Product Deep Dive: Molecular Mechanisms and Production Evolution

2.1 Physicochemical Properties and Mechanisms

GVSWGLR is a short, amphipathic heptapeptide: two hydrophobic branched residues flank a polar serine, an aromatic tryptophan sits at the centre of the sequence, and a C-terminal arginine carries the only ionisable side chain other than the termini. Its small size gives it a well-behaved chromatographic profile and a mass comfortably inside the range resolved by routine high-resolution instruments. For procurement purposes the important consequences are its fluorescence, its sensitivity to oxidative stress and its strongly basic character at the C-terminus, all of which shape specification and handling.

• Mass, Charge and Detection Profile: The sequence gives an average molecular mass of approximately 774 Da for the free peptide, with the trifluoroacetate load reported separately; the arginine guanidinium group and the free N-terminus give a net positive charge at neutral pH and a theoretical isoelectric point well above 9, while the indole ring provides intrinsic fluorescence useful for detection but also the primary site of oxidative degradation.
• Sequence-Specific Degradation Chemistry: With no asparagine or glutamine present, the deamidation pathway that plagues longer peptides is absent, and the specification burden concentrates instead on tryptophan oxidation to oxindolylalanine and related photo-oxidation products, on serine dehydration, and on moisture uptake by the lyophilised powder.

2.2 Synthesis and Manufacturing Technologies

Manufacture follows the standard route classes of the peptide industry: stepwise solid-phase assembly using fluorenylmethoxycarbonyl protection on a polymeric support, or a hybrid approach in which a protected fragment is assembled on resin and completed in solution. Suppliers describe capability at route-class level and do not disclose resin loadings, coupling reagents or cycle times outside a confidentiality agreement, and buyers should be sceptical of any vendor that presents no process rationale at all. What distinguishes capable manufacturers is how they protect the indole during cleavage, how they set the counter-ion, and how thoroughly they characterise the oxidation products that this sequence generates.

• Assembly, Deprotection and Indole Protection: Residue-level coupling control with in-process monitoring, careful choice of acidolytic cleavage conditions and of scavenger systems that limit alkylation and oxidation of the tryptophan indole, followed by global deprotection under conditions selected to minimise formation of tryptophan adducts.
• Preparative Purification, Salt-Form Setting and Lyophilisation: Preparative reversed-phase HPLC with pooling against analytical release criteria, deliberate salt-form selection with exchange to acetate or hydrochloride where residual trifluoroacetate must be reduced, subsequent desalting, concentration and lyophilisation under a cycle designed to give a stable, low-moisture cake.

2.3 Core Application Matrix

• Central Nervous System and Ion Channel Research: Supply of characterised material to academic, biotechnology and contract research laboratories investigating two-pore domain potassium channel pharmacology and sortilin-related receptor interactions in cellular and animal models, where batch identity determines reproducibility.
• Analytical Reference and Method Development: Use as a characterised material for HPLC and LC-MS method development, system suitability and forced-degradation work, including the deliberate mapping of tryptophan oxidation products as marker peaks in a stability-indicating method.
• Process and Formulation Research Support: Support for clients evaluating counter-ion options, solubility and excipient compatibility, lyophilisation cycle design and container-closure selection under research conditions, with no implied clinical, consumer or dietary application.

III. Global Market Supply-Demand Landscape and Export Trends

3.1 Demand Drivers and Market Shifts

Demand for short research peptides of this type tracks academic and biotech funding cycles rather than industrial consumption, and it has moved decisively from catalogue buying toward project buying. Buyers now request defined analytical packages, documented impurity profiles, change-control undertakings and end-use declarations, and they consolidate with suppliers able to support both research and later GMP manufacture. In parallel, unapproved research-chemical channels offering peptides directly to individuals have drawn sustained regulatory attention in the European Union and the United States. Legitimate suppliers do not serve that channel.

3.2 Capacity Distribution and Export Flows

Synthesis capacity for short peptides is abundant and concentrated in China and India, where protected amino acids, resins, coupling reagents and preparative purification throughput are cheapest and most scalable, with a smaller high-compliance tier in Europe and North America serving regulated and reference-grade campaigns. For a heptapeptide the binding constraints are not reactor hours but analytical instrumentation, method-validation capability and qualified cold-chain logistics. Lead times are typically governed by the synthesis queue, purification batching and the release-testing calendar.

3.3 Market Bifurcation and Pricing Dynamics

The market divides between catalogue material sold with a minimal certificate and certified research material supported by accurate-mass identity, assigned peptide content, residual trifluoroacetate and solvent data, water content and a stated related-substance profile. The price multiple between the two is substantial, and it reflects analytical labour, not chemical difficulty. Because the salt and water burden in a lyophilised peptide can shift the effective amount of peptide delivered by a fifth or more, a low headline price per vial is frequently the most expensive option per milligram of actual peptide, and any quotation omitting counter-ion and content data should be treated as incomplete.

IV. In-depth Analysis of Global Compliance and Regulatory Barriers

With no approved therapeutic indication, the compliance perimeter is defined by what the material must not become: a medicinal product, a food or dietary supplement ingredient, a cosmetic ingredient or a retail consumer article. Lawful trade rests on consistent classification as Research Use Only material, on documentation accompanying every consignment, and on documented qualification of every customer. The instruments below are those buyers and suppliers should be able to cite during an audit.

4.1 European Market: REACH, CLP, and Sector-Specific Directives

• REACH and CLP Treatment of Research Peptides: Supply for scientific research and development commonly falls outside full registration where the relevant provisions apply, but the supplier must document that position, issue a compliant safety data sheet and CLP-aligned labelling, and screen the substance against candidate-list and restriction obligations before export.
• Unapproved Peptide Products and Border Control: National competent authorities and customs treat peptides offered for human administration as unlicensed medicinal products; placing such material on the EU market is unlawful, and consignments without a credible Research Use Only end-use declaration risk detention and seizure.

4.2 North American Market: TSCA, EPA, and FDA Regulations

• FDA Position on Unapproved Peptides: There is no approved drug product containing this heptapeptide; material promoted for human use would be an unapproved new drug and misbranded, and FDA enforcement history on unapproved peptide products should govern how quotations, labels and listings are worded.
• Anti-Doping Compliance Screening Relevance: Peptide hormones, growth factors and related substances sit within prohibited classes under the World Anti-Doping Code, and shorter bioactive peptides are routinely examined in that context; suppliers should therefore maintain Know-Your-Customer and end-use records that keep research material outside sport-diversion channels.

4.3 The Critical Hurdle: Quality Control and Safety Limits

V. Green Trade Barriers and ESG in Manufacturing

Peptide manufacturing carries a distinctive environmental profile driven by solvent consumption during coupling, washing and preparative chromatography, by fluorinated cleavage reagents and by the energy intensity of lyophilisation and cold storage. Even a short sequence consumes multiples of its own mass in solvent, and environmental questions now form part of routine supplier qualification by pharmaceutical and institutional buyers.

5.1 Carbon Footprint and Circular Economy

The principal contributors are aprotic polar solvents used in coupling and washing, acetonitrile consumed in preparative reversed-phase chromatography, and electricity for freeze-drying and refrigerated storage. Practical mitigations include solvent recovery by distillation, substitution toward greener coupling media, pooling strategies that reduce chromatographic runs, and heat recovery on lyophiliser condensers. Suppliers able to report solvent intensity per gram released and to evidence a Scope 1 and Scope 2 inventory under ISO 14001 increasingly win preference in institutional tenders.

5.2 Sustainable Sourcing and Traceability

Buyers should require documented origin of protected amino acids and resins, a statement on the absence of animal-derived materials with TSE and BSE status, confirmation that no material of human origin is used, and traceability records retained in the batch file. Where a project may later move into a regulated campaign, the same expectation extends to change control, so that any resin, reagent or solvent change is notified in advance and the comparability of the impurity profile reassessed.

VI. Supply Chain Resilience and Export Logistics

Lyophilised peptide is more robust in transit than solution, but it remains a hygroscopic solid whose assigned peptide content drifts if vials are opened or stored in humid air, and whose oxidation profile can move if a cold chain fails or if the material is exposed to light. Logistics planning should therefore assume sealed, light-protected, desiccated packaging, controlled or refrigerated transit with documented excursion handling, and a validated frozen configuration for any solution aliquot or intermediate.

6.1 Packaging Standards and Moisture/Contamination Control

• Container Closure and Light and Moisture Control: Amber glass or inert polymer vials with polytetrafluoroethylene-lined closures, sealed under nitrogen or argon where appropriate, with desiccant and oxygen scavenger, light-blocking secondary packaging and a residual-moisture statement recorded on the certificate of analysis.
• Labelling and Documentation Set: Labels carrying CAS 1801959-12-5, batch number, sequence, salt form, net peptide content, storage condition and the Research Use Only statement, supported by safety data sheet, certificate of analysis and tamper-evident sealing.

6.2 Dangerous Goods Identification and Transit Protocols

Dried peptide is normally shipped at ambient or refrigerated temperature in a validated insulated configuration, while solution aliquots and intermediates move frozen with dry ice or phase-change materials under continuous temperature logging and defined excursion thresholds. Peptides themselves are generally not classified as dangerous goods, but any accompanying solvent or preserved solution can change the classification, requiring UN-specification packaging, a dangerous-goods declaration under IMDG, ADR or IATA rules and a trained shipper; misdeclaration of such consignments remains a frequent cause of detention. Air freight is preferred for speed and temperature stability.

VII. Enterprise Global Expansion Strategy Guide

For CDMOs and exporters building durable positions in short research peptide supply, three priorities dominate: analytical credibility, compliance discipline, and the ability to carry a client from research into GMP without restarting development.

1. Sell the Analytical Package: Differentiate on assigned peptide content, counter-ion and residual-solvent reporting, high-resolution mass-spectrometric identity and a documented related-substance profile including tryptophan oxidation products, with methods developed and validated along ICH Q2(R1) and Q14 principles.
2. Institutionalise Customer Qualification: Apply documented Know-Your-Customer screening, end-use declarations and order-screening rules that exclude research-chemical retail channels, retain evidence of decisions on declined orders, and train commercial staff to recognise enquiry patterns that indicate diversion rather than research.
3. Design the RUO-to-GMP Bridge: Preserve raw-material, method and batch records from the first campaign so that ICH Q7 and Q11 expectations, an occupational exposure band derived from a health-based exposure limit, and eventual tech transfer into a GMP suite do not repeat development work or trigger comparability surprises.

VIII. Conclusion

CAS 1801959-12-5 is a short, tractable heptapeptide whose commercial difficulty lies almost entirely outside the synthesis. Assembly is routine; what determines value is whether the supplier can control and report tryptophan oxidation, set the counter-ion deliberately, assign peptide content honestly, and ship the material under conditions that preserve that assignment. Buyers who evaluate suppliers on those four criteria will consistently obtain material that supports reproducible data.

The compliance perimeter is equally non-negotiable. This peptide has no approved therapeutic indication, is supplied as Research Use Only material, is not for human or veterinary use and is not a finished consumer or dietary product; no antidepressant or other therapeutic claim may be attached to it. Organisations that combine rigorous characterisation with disciplined customer qualification, end-use declaration and documentation control will be those able to serve legitimate research demand as scrutiny of unapproved peptide products intensifies.

IX. Industry Resource Connection and Supplier Ecosystem

Powered by Guidechem

This white paper is exclusively compiled by the Guidechem Intelligence Team based on global customs data, regulatory databases, and industry research. Guidechem is a leading global B2B chemical platform, dedicated to connecting global buyers with verified, high-quality manufacturers.

Guidechem Global L-Arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl- (PE 22-28 peptide) Supplier Ecosystem List

Relying on Guidechem's extensive global database, we have mapped the core participants in the current global L-Arginine, glycyl-L-valyl-L-seryl-L-tryptophylglycyl-L-leucyl- (PE 22-28 peptide) supply chain:

• China Short-Peptide Synthesis and Raw-Material Base: Chinese producers supply protected amino acids, resins and high-throughput preparative purification, delivering research campaigns quickly and competitively; buyers should verify analytical depth, oxidation control, cold-chain practice and end-use screening rather than assume equivalence across vendors.
• India GMP-Linked Peptide Capability: Indian manufacturers combine cost-competitive synthesis with DMF and GMP experience from generic API work, making them strong partners for projects expected to progress from research supply into regulated manufacture.
• European Union High-Compliance Peptide and Reference-Grade Tier: EU CDMOs and reference-material producers offer ISO 17034-style certification, health-based-exposure-limit containment assessment and audit-ready documentation, suited to buyers whose compliance function requires the strictest chain of custody.